BluePath Capital Management
TMO icon

BluePath Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

BluePath Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.74M Buy
2,571
+290
+13% +$172K 0.91% 31
2026
Q2 		$1.14M Buy
+2,281
New +$1.09M 0.63% 65
2024
Q4 		– Sell
-389
Closed -$241K – 110
2024
Q3 		$241K Buy
389
+11
+3% +$6.51K 0.15% 93
2024
Q2 		$209K Sell
378
-50
-12% -$28.6K 0.15% 104
2024
Q1 		$249K Buy
428
+58
+16% +$32.5K 0.19% 104
2023
Q4 		$201K Buy
370
+51
+16% +$24.7K 0.17% 102
2023
Q3 		$161K Buy
+319
New +$170K 0.15% 113

Other funds holding TMO

Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $19.7B AUM 7.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Veritas Asset Management
Veritas Asset Management London, United Kingdom $5.37B AUM 7.96% 1-Year Est. Return

BluePath Capital Management's TMO Position: Q3 2026 in Review

BluePath Capital Management increased its Thermo Fisher Scientific (TMO) stake by 13% in Q3 2026, buying an estimated $172K and bringing the position to 2,571 shares worth $1.74M. The position accounts for 0.91% of the portfolio, ranked #31.

BluePath Capital Management first reported a position in TMO in Q3 2023 and has held it in 7 quarters since. 1,473 funds tracked by Wall St. Rank hold TMO as of Q3 2026.

  • BluePath Capital Management held 2,571 shares of Thermo Fisher Scientific worth $1.74M as of Q3 2026.
  • BluePath Capital Management bought 290 Thermo Fisher Scientific shares in Q3 2026, an estimated $172K.
  • Thermo Fisher Scientific made up 0.91% of BluePath Capital Management's portfolio in Q3 2026, its #31 holding.
  • BluePath Capital Management first reported a position in Thermo Fisher Scientific in Q3 2023 and has held it in 7 quarters since.
  • 1,473 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2026.

Based on BluePath Capital Management's 13F filing for Q3 2026, filed 26 Oct 2026.